

Information Governance

9 July 2021

Our Ref: RFI 38933

Dear

**Freedom of Information Act 2000 or
Environmental Information Regulations 2004**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to dermatology biological drug treatments which you requested on 7 May 2021.

Please accept my apologies for the delay in responding to your correspondence as the Information Governance Department is dealing with a large number of requests for information, including a backlog of requests as a result of the Covid-19 pandemic which had a major impact across services. Thank you for your patience.

A response to each of the questions raised has been provided by the Hospital Services Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital (informationgovernance@setrust.hscni.net) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

Cathryn Hedley

Q1. Could you please provide the numbers of patients treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

A1. Please see Table 1 below with the numbers of patients treated in the last 3 months by the Dermatology department.

Table 1:

Treatments/Medication	Number of Patients Treated
Adalimumab – Humira	6
Adalimumab Biosimilar	68
Apremilast	Nil
Brodalumab	<5
Certolizumab	< 5
Dimethyl fumarate	Nil
Etanercept – Enbrel	Nil
Etanercept Biosimilar	<5
Guselkumab	24
Infliximab – Remicade	<5
Infliximab Biosimilar	<5
Ixekizumab	17
Risankizumab	16
Secukinumab	30
Tildrakizumab	Nil
Ustekinumab	25

NB. You will note that some of the numbers have been masked and this is due to small numbers within a geographical area.

Q2. For the patients treated by the Dermatology department in the last three months with any of the above drugs, can you please provide the total number of paediatric (up to age 16) versus adult patients?

A2. All patients treated for the drugs listed above were adults.

Q3. Could you please provide the numbers of patients treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

A3. Please see Table 2 below with the numbers of patients treated in the last 3 months by the Gastroenterology department.

Table 2:

Treatments/Medication	Number of Patients Treated
Adalimumab – Humira	12
Adalimumab Biosimilar	150
Golimumab	5
Infliximab – Remicade	<5
Infliximab Biosimilar	192
Tofacitinib	7
Ustekinumab	97
Vedolizumab	65

NB. You will note that some of the numbers have been masked and this is due to small numbers within a geographical area.